Messaggi
6hey guys
I have become aware of $GMAB (+0,47%) became attentive
looks brutally undervalued
fundamentally great sales profits are rising etc.
there are only supposed to have been complaints from japan and abbvie
but shouldn't that be priced in?
how do you currently see the value
VG THANKS
During my first year of investing, I bought a lot of shares that I didn't really understand what they were doing. In the course of my restructuring, I would like to reduce my number of shares from almost 30 to 15 in the long term. However, I want to do this over a longer period of time, as these are not bad companies.
Shares that I want to sell
Apple $AAPL (+0,26%)
Medpace $MEDP (-0,94%)
ResMed $RMD (-0,09%)
Shimano $7309 (+1,25%)
LVMH $MC (+0,4%)
Genmab $GMAB (+0,47%)
Pernod Ricard $RI (+2,31%)
Pilbara Minerals $PLS (-3,08%)
Sixt $SIX2 (-0,48%)
McDonald's $MCD (+0,5%)
Domino's Pizza $DPZ (-1,75%)
Crowdstrike $CRWD (-6,19%)
Salesforce $CRM (-2,41%)
Nvidia $NVDA (-3,63%)
Just to clarify, I am not selling these companies because they are bad companies, but because they no longer fit into my investment strategy. I will only invest in companies that are not included in the classic world ETFs, but which I nevertheless understand well.
My question would be what you generally think of this and in which order you would sell the companies listed (as they are listed, this is my preferred order)
Hi there!
First off, I want to introduce myself. I'm a 24-year-old who's spent about two years diving into the world of investing. Though I’m just starting, I’d love to share a bit of my journey with you all.
My Beginnings
I’ve always had a unique approach to life and investments, which often feels different from most people I know. I started working young, driven by a goal to save €10,000. For someone living in Portugal, where building wealth takes time, this felt like a mountain to climb.
Unfortunately, at 18, I fell victim to a scam and lost €5,000 in my first year of trying to invest. It was a harsh lesson. My family thought I was naive for believing I could become wealthy quickly through trading. They’d never ventured into investments, so I was forging a path on my own.
Hitting Rock Bottom
After the scam, I swore off markets altogether. I moved to Spain to try earning more, but the isolation and inability to grow my savings left me depressed. It was during this tough time that my boss introduced me to Bitcoin.
He told me: “Diogo, buy Bitcoin. This could change your life. Don’t spend on cars or houses—invest in this!” At first, I thought he was crazy. Bitcoin was volatile, and I couldn’t imagine risking so much. But his passion stayed with me, and I began paying attention to the market.
Turning Things Around
In 2022, I returned to Portugal, reuniting with family, friends, and a sense of purpose. I found a stable job—not well-paying, but it gave me a foundation to rebuild. Slowly, I started meeting people active in the markets, shifting my mindset, and planning my future more thoughtfully.
I set a goal to save €10,000 again, this time with a clear strategy. By saving at least €200 a month and focusing on long-term growth (like investing in the S&P 500), I envisioned reaching €1 million by the time I turn 40.
Lessons and Progress
By the end of 2023, I came close to my goal, saving €9,500. My biggest win was investing in NVIDIA ($NVDA (-3,63%) ), which gave me a 55% return in less than a year!
In 2024, I made another significant investment—this time in myself. I used some savings to fix my teeth, boosting my confidence. Despite that expense, I managed to grow my investments to €23,000 by year's end.
My Current Strategy
This year, I’m focusing on stocks and crypto that are undervalued but have strong potential for growth. My portfolio includes:
Cripto:
Final Thoughts
My goal is to end this year with €40,000 invested, to be able to get half of it into the real state,It’s ambitious, but I’ve learned that persistence and patience can yield great rewards.
I’ll keep you all updated on my journey. Best of luck to everyone on yours!
Diogo Cordas
Genmab Q3 2024 $GMAB (+0,47%)
Financial performance:
Balance sheet overview:
Profit and loss account:
Cash flow overview:
Key ratios and profitability metrics:
Competitive position:
Forecasts and management commentary:
Risks and opportunities:
Summary of results:
Positive aspects:
Negative aspects:
Genmab A/S
Company presentation
Genmab A/S is a Danish biotechnology company specializing in the development of innovative therapies to fight cancer. Founded in Copenhagen in 1999, the company is primarily dedicated to the research and production of monoclonal antibodies for oncology treatment. An outstanding product of $GMAB (+0,47%) is the proprietary Duobody® technology platform, which aims to optimize the treatment of various types of cancer.
Core business and key products
Genmab's core business is the development and commercialization of antibody therapies. Key products include:
Mission and vision
Genmab's mission is to develop innovative and differentiated antibody products that sustainably improve the lives of cancer patients. The company's vision is to be a leader in oncology through pioneering research and development in antibody therapy.
Historical development
Founded in 1999, Genmab went public on the Copenhagen and Frankfurt stock exchanges in 2000. The IPO raised 1.56 billion Danish kroner (approximately 209 million euros) for the company. In 2002, Genmab was delisted again in Frankfurt.
Business model & core competencies
Genmab's business model is based on the development and commercialization of innovative antibody therapies. The company's core competencies lie in the research of monoclonal antibodies and the Duobody® technology platform. This technological expertise gives Genmab a significant competitive advantage in the field of cancer therapies.
Future prospects & strategic initiatives
Genmab is continuously investing in the further development of its antibody technologies and the expansion of its product pipeline. This promising pipeline points to strong growth potential.
Market position & competition
Genmab has established itself as a major player in the field of antibody therapies. The company competes with large pharmaceutical companies such as $ROG (+1,31%) , $NOVN (+1,73%) and $GSK (-0,74%) , with which it also has development and marketing partnerships. Genmab's market position is strengthened by its innovative technologies and strong partnerships.
Total Addressable Market (TAM)
The global market for monoclonal antibodies in cancer therapy is growing steadily. In view of the increasing incidence of cancer and the growing demand for targeted therapies, Genmab has considerable growth potential.
Development
Sales are growing at a CAGR of 31%, while the gross margin is growing at a CAGR of 30%. EBIT shows a fluctuating but increasing development with a CAGR of 20%, and net profit is growing at a CAGR of 22%. The number of shares issued is also falling.
Darzalex is clearly the sales driver and therefore the company's most important product. Nevertheless, the other products are also making progress and growing steadily.
Licensing has enabled the company to maintain a gross margin of 100 % for a long time. However, as it is now beginning to take marketing into its own hands, this margin is expected to decline. At the same time, however, the operating and net profit margins should increase. Overall, however, the margins are encouraging, with a net profit margin of over 25%
SBC has risen well, but remains in line with the company's performance. Moreover, there is no dilution of shares due to the buybacks. The free cash flow (FCF) has also increased solidly, so there is nothing to complain about here.
The shareholder yield is just under 4%. The ratio of enterprise value (EV) to EBITDA falls when EBITDA rises and market capitalization falls. In addition, the ratio of net debt to EBITDA is negative, which is also positive.
Genmab's capital efficiencies are exceptional and are all above 10%.
Conclusion
Genmab A/S, with its focus on innovative antibody therapies and a promising product pipeline, is well positioned to capitalize on the growing opportunities in the field of cancer treatment. The company's solid financial performance and strategic partnerships highlight its potential for future growth and innovation in the biotechnology sector.
Although the share price has fallen recently, Genmab still has significant growth opportunities ahead. The promising pipeline and the upcoming launch of new products are expected to contribute significantly to operating income. In addition, the company has an impressive capital efficiency and benefits from the positive economic situation in Denmark.
Denmark has traditionally established itself as a center for medical technology and biotechnology. The explosive development of companies like Novo Nordisk could also have positive spillover effects for other medical companies, including Genmab. Overall, this is an interesting company that I believe is undervalued based on my DCF analysis.
+ 6
Newsletter & Blog
https://topicswithhead.beehiiv.com/
Structure
$NVDA (-3,63%)
: The brain behind the AI cycle https://getqu.in/R8kJvx/
$CRWD (-6,19%)
: The falcon that can no longer fly? https://getqu.in/xAZJbb/
$D05 (+0,91%)
: The best bank in the world? https://getqu.in/Mv6fLf/
$HOOD (-7,16%)
: Savior of small investors or master of the silent raid?"
The venture play of the $XTP (-0,81%)
. Participation in the self-proclaimed "European Charles Schwab". https://getqu.in/T5Fc49/
$ORI (+1,27%)
The share for opis? https://getqu.in/HKAf7p/
$SNOW (-3,37%)
Is the ❄️ melting away or growing into an iceberg https://getqu.in/FundGB/
$ASML (-0,72%)
: The best technology company in Europe- The brains behind every smart chip https://getqu.in/JWXYkC/
$DDOG (-4,67%)
The pit bull of data analysis https://getqu.in/YpHawB/
$AFX (-0,59%)
: The share that catches the eye 🔍 https://getqu.in/oDGSmr/
🚜$DE (-2,08%)
: From king of the field to prince of construction? https://getqu.in/27HkzI/
$CDR (+0,8%)
: Of sorcerers and cyberpunks - the masters of the digital worlds 🏙️ https://getqu.in/dYjIcI/
🏎 $FWONK
: Pole position in the business of high-speed spectacle 🏁https://getqu.in/lY15B7/
💶$AMUN (-0,07%)
: Europe's financial architect - Is he building the most solid fortunes? 🏗️ https://getqu.in/Erlpxb/
$IVSA
AB: A Swedish investment powerhouse with vision https://getqu.in/kI1lgD/
📊$MSCI (+1,13%)
: More than just indices - the secret data king of the financial markets 👑 https://getqu.in/8IdYUC/
Man and machine $MUM (+0,16%)
https://getqu.in/yk2ee7/
Genmab A/S $GMAB (+0,47%)
https://getqu.in/eJDAxs/
Prosus NV- The Tencent Play $PRX (+0,17%)
https://getqu.in/E8PMgz/
Futu Holdings- The Fintech Broker from China $FUTU (+1,75%)
https://getqu.in/2CfdRy/
⚡ Gas giants of the future: Who will lead the energy race? 🏁
✨ Who is the beauty king? A look at the stars of the cosmetics stocks ✨ https://getqu.in/C9QiOo/
🌐 Stock market battle: Deutsche Börse, ICE, Euronext, NASDAQ - who dominates trading? 📊 https://getqu.in/7mcYEJ/
⚙️ Giants of industry: Siemens, Schneider Electric, GE & ABB in a power comparison 💪https://getqu.in/iL6sJ3/
✈️ Aviation titans compared: Airbus, Boeing, Embraer - who will take off? 🚀https://getqu.in/Xfmo8G/
🍽️ Giants at the dinner table: Nestlé, Unilever & Co. - Who serves up the biggest success?
Haute Finance: LVMH,Richemont ,Kering and Hermès - The stock market défilé of the luxury giants https://getqu.in/HmleWd/
Celsius Holdings vs Monster Beverage. Who is the better buy for the future? https://getqu.in/mQIVSZ/
Number crunchers of the financial world: Moody's vs. S&P in a data duel https://getqu.in/s5l7qm/
💳 The card game of the giants: Visa, Amex, Mastercard - who will win the payment poker? 🃏https://getqu.in/Qb7UAo/
⛏️ Titans of the deep: Rio, Glencore, BHP, Vale - Who will dig up the biggest profit? 💎
Hardware of data: Arista, Cisco, Juniper and HPE in the infrastructure race https://getqu.in/dHfciF/
Money today or tomorrow?
Annuity
Bond valuation
Stock valuation
Market efficiency
Portfolio theories
Why domestic ETF providers are worth considering
Diabetes injection. Miracle cure or economic injection? https://getqu.in/xc3C7R/
I migliori creatori della settimana
